Vigabatrin
(Synonyms: 氨己烯酸; γ-Vinyl-GABA) 目录号 : GC37905
Vigabatrin是 γ-氨基丁酸转氨酶 (GABA-T) 的不可逆抑制剂,具有提高脑 GABA 水平和增强抑制性神经传递的强效活性。
Cas No.:68506-86-5
Sample solution is provided at 25 µL, 10mM.
Vigabatrin is an irreversible inhibitor of γ-aminobutyric acid transaminase (GABA-T), with potent activity in elevating brain GABA levels and enhancing inhibitory neurotransmission [1-3]. Vigabatrin is commonly used to treat refractory epilepsy [4].
In glioblastoma multiforme cell (13–06-MG), concentration-dependent inhibitory effect of Vigabatrin (0.3-100μM; 24h) on the activity of IKCa channels [5]. In Caco-2 and MDCK cells, Vigabatrin (30mM; 24h) inhibits the uptake of taurine in Caco-2 and MDCK cells to 34 ± 3 and 53 ± 2% [6]. In U87 cells, Vigabatrin administration has a growth-promoting effect on cells [7].
In Tsc1GFAPCKO mice, Vigabatrin (50mg/kg, 100mg/kg, 200mg/kg; ip; 10 weeks) treatment decreased the development of seizures and modestly improved survival [8]. In C57BL/6J mice, after of Vigabatrin (140mg/kg; ip; 4 weeks) treatment, ERG b-wave amplitude was enhanced, and amplitudes of oscillatory potentials were reduced [9]. In C57BL/6J mice, Vigabatrin (35-140mg/kg; sc; 14d) treatment induces amino acid disturbances in mice [10].
References:
[1]. French JA. Vigabatrin. Epilepsia. 1999 May; 40: s11-6.
[2]. James Willmore L, Abelson MB, Ben‐Menachem E, et al. Vigabatrin: 2008 update. Epilepsia. 2009 Feb; 50(2): 163-173.
[3]. Ben‐Menachem E. Mechanism of action of vigabatrin: correcting misperceptions. Acta neurologica scandinavica. 2011 Dec; 124: 5-15.
[4]. Tartara A, Manni R, Galimberti CA, et al. Vigabatrin in the treatment of epilepsy: a double‐blind, placebo‐controlled study. Epilepsia. 1986 Dec; 27(6): 717-723.
[5]. Hung TY, Huang HY, Wu SN, et al. Depressive effectiveness of vigabatrin (γ-vinyl-GABA), an antiepileptic drug, in intermediate-conductance calcium-activated potassium channels in human glioma cells. BMC Pharmacology and Toxicology. 2021 Dec; 22: 1-9.
[6]. Plum J, Nøhr MK, Hansen SH, et al. The anti-epileptic drug substance vigabatrin inhibits taurine transport in intestinal and renal cell culture models. International journal of pharmaceutics. 2014 Oct 1; 473(1-2): 395-397.
[7]. Lee CY, Lai HY, Chiu A, et al. The effects of antiepileptic drugs on the growth of glioblastoma cell lines. Journal of neuro-oncology. 2016 May; 127: 445-453.
[8]. Zhang B, McDaniel SS, Rensing NR, et al. Vigabatrin inhibits seizures and mTOR pathway activation in a mouse model of tuberous sclerosis complex. PLoS One. 2013 Feb 20; 8(2): e57445.
[9]. Chan K, Hoon M, Pattnaik BR, et al. Vigabatrin-induced retinal functional alterations and second-order neuron plasticity in C57BL/6J mice. Investigative Ophthalmology & Visual Science. 2020 Feb 7; 61(2): 17.
[10]. Walters DC, Arning E, Bottiglieri T, et al. Metabolomic analyses of vigabatrin (VGB)-treated mice: GABA-transaminase inhibition significantly alters amino acid profiles in murine neural and non-neural tissues. Neurochemistry international. 2019 May 1; 125: 151-162.
Vigabatrin是 γ-氨基丁酸转氨酶 (GABA-T) 的不可逆抑制剂,具有提高脑 GABA 水平和增强抑制性神经传递的强效活性 [1-3]。Vigabatrin常用于治疗难治性癫痫 [4]。
在多形性胶质母细胞瘤细胞(13-06-MG)中,Vigabatrin(0.3-100μM;24h)对IKCa通道活性具有浓度依赖性的抑制作用 [5]。在Caco-2和MDCK细胞中,Vigabatrin(30mM;24h)可抑制Caco-2和MDCK细胞对牛磺酸的摄取,使其分别降低34±3%和53±2% [6]。在U87细胞中,Vigabatrin给药促进细胞生长的作用 [7]。
在Tsc1GFAPCKO小鼠中,Vigabatrin(50mg/kg、100mg/kg、200mg/kg;ip;10周)治疗可减少癫痫发作,并略微提高生存率 [8]。在C57BL/6J小鼠中,Vigabatrin(140mg/kg;ip;4周)治疗后,ERG b波幅度增强,振荡电位幅度降低 [9]。在C57BL/6J小鼠中,Vigabatrin(35-140mg/kg;sc;14d)治疗可诱发小鼠氨基酸紊乱 [10]。
Cell experiment [1]: | |
Cell lines | Glioblastoma multiforme cell (13–06-MG) |
Preparation Method | The glioblastoma multiforme cell (13–06-MG) were cultured at a density of 106/mL in high glucose (4g/L) Dulbecco’s modified Eagle media supplemented with 10% heat-inactivated fetal bovine serum, 100 U/mL penicillin and 10μg/mL streptomycin. Cells were maintained at 37 ℃ in a 5% CO2 incubator as monolayer cultures and thereafter sub-cultured weekly. Fresh media was added every 2–3 days in order to ensure a healthy cell population. To evaluate concentration-dependent inhibition of VGB on the probability of IKCa channels that would be open, we kept 13–06-MG cells to be bathed in normal Tyrode’s solution containing 1.8mM CaCl2, and each cell examined was voltage-clamped at -80mV relative to the bath. The probability of channel opening was measured in the control or during cell exposure to different concentrations (0.3-100μM) of Vigabatrin; and, these values were then compared with those taken after the addition of TRAM-34 (3μM). TRAM-34 is a known selective blocker of IKCa channels. |
Reaction Conditions | 0.3-100μM; 24h |
Applications | Concentration-dependent inhibitory effect of Vigabatrin on the activity of IKCa channels. |
Animal experiment [2]: | |
Animal models | Tsc1GFAPCKO mice |
Preparation Method | Three-week-old Tsc1GFAPCKO mice were treated with vehicle (saline) or Vigabatrin at different doses (50, 100, 200mg/kg/day, i.p) for one week for Western blot and GABA concentrations, for four weeks (200mg/kg/day) for histology and immunohistochemistry analysis, and for up to 10 weeks (200mg/kg/day) for video-EEG monitoring. |
Dosage form | 50mg/kg, 100mg/kg, 200mg/kg; ip; 10 weeks |
Applications | Vigabatrin treatment decreased the development of seizures and modestly improved survival in Tsc1GFAPCKO mice. |
References: |
Cas No. | 68506-86-5 | SDF | |
别名 | 氨己烯酸; γ-Vinyl-GABA | ||
化学名 | 4-amino-5-hexenoic acid | ||
Canonical SMILES | C=CC(N)CCC(O)=O | ||
分子式 | C6H11NO2 | 分子量 | 129.16 |
溶解度 | 10mg/mL in PBS, pH 7.2 | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
![]() |
1 mg | 5 mg | 10 mg |
1 mM | 7.7423 mL | 38.7117 mL | 77.4234 mL |
5 mM | 1.5485 mL | 7.7423 mL | 15.4847 mL |
10 mM | 0.7742 mL | 3.8712 mL | 7.7423 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet